Phase II study of MK8669 in patients with metastatic bone or soft-tissue sarcoma (8669-030)MK8669 is a small molecule mTOR inhibitor and rapamycin analogue. mTOR is a serine/threonine kinase located downstream of the PI3K/Akt signalling pathway. The gene discussed is MARK2; the disease is soft tissue sarcoma.